Jared Radbel

Has grant

Assistant Professor

Rutgers New Jersey Medical School

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Jared Radbel is an Assistant Professor at Rutgers Robert Wood Johnson Medical School in the United States. His research primarily focuses on critical care management and treatment strategies for COVID-19, with recent publications examining the use of tissue plasminogen activator, anticoagulation, and respiratory support systems. He also investigates the impact of pre-existing conditions on COVID-19 outcomes, particularly in hospitalized patients.

Recent Grants

Grant: Close

Role of Macrophage Efferocytosis in Ozone-Induced ARDS

Open Date: 2020-09-01

Close Date: 2025-08-01

Articles (10)

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

UNITED STATES

View details

Jag Sunderram

Professor

Rutgers New Jersey Medical School

UNITED STATES

View details

Aquino Williams

Chief Resident

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Jared Radbel

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (10)

Tissue Plasminogen Activator in Critically Ill Adults with COVID-19.

Physiologic Improvement in Respiratory Acidosis Using Extracorporeal Co2 Removal With Hemolung Respiratory Assist System in the Management of Severe Respiratory Failure From Coronavirus Disease 2019.

Montelukast in hospitalized patients diagnosed with COVID-19.

Prone Positioning and Survival in Mechanically Ventilated Patients With Coronavirus Disease 2019-Related Respiratory Failure.

Thrombosis, Bleeding, and the Observational Effect of Early Therapeutic Anticoagulation on Survival in Critically Ill Patients With COVID-19.

Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19.

AKI Treated with Renal Replacement Therapy in Critically Ill Patients with COVID-19.

Observational study of the use of recombinant tissue-type plasminogen activator in COVID-19 shows a decrease in physiological dead space.

In-hospital cardiac arrest in critically ill patients with covid-19: multicenter cohort study.

Characteristics and Outcomes of Individuals With Pre-existing Kidney Disease and COVID-19 Admitted to Intensive Care Units in the United States.

Collaborators (7)

Rajany Dy

Benjamin Wu

Amee Patrawalla

Isha Puri

Ladan Golestaneh

Jag Sunderram

Aquino Williams

Make your next move.